256 related articles for article (PubMed ID: 17063150)
21. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder.
Yang B; Chan RC; Jing J; Li T; Sham P; Chen RY
Am J Med Genet B Neuropsychiatr Genet; 2007 Jun; 144B(4):541-50. PubMed ID: 17440978
[TBL] [Abstract][Full Text] [Related]
23. Functional analysis of intron 8 and 3' UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants.
Hill M; Anney RJ; Gill M; Hawi Z
Pharmacogenomics J; 2010 Oct; 10(5):442-7. PubMed ID: 20029387
[TBL] [Abstract][Full Text] [Related]
24. Evidence of an association between 10/10 genotype of DAT1 and endophenotypes of attention deficit/hyperactivity disorder.
Agudelo JA; Gálvez JM; Fonseca DJ; Mateus HE; Talero-Gutiérrez C; Velez-Van-Meerbeke A
Neurologia; 2015 Apr; 30(3):137-43. PubMed ID: 24461309
[TBL] [Abstract][Full Text] [Related]
25.
Naumova D; Grizenko N; Sengupta SM; Joober R
World J Biol Psychiatry; 2019 Jul; 20(6):486-495. PubMed ID: 29182037
[No Abstract] [Full Text] [Related]
26. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
27. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder.
Cheon KA; Jun JY; Cho DY
Int Clin Psychopharmacol; 2008 Sep; 23(5):291-8. PubMed ID: 18703939
[TBL] [Abstract][Full Text] [Related]
28. Genetic imaging study with [Tc-
Akay AP; Kaya GÇ; Kose S; Yazıcıoğlu ÇE; Erkuran HÖ; Güney SA; Oğuz K; Keskin D; Baykara B; Emiroğlu Nİ; Eren MŞ; Kızıldağ S; Ertay T; Özsoylu D; Miral S; Durak H; Gönül AS; Rohde LA
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():294-300. PubMed ID: 29684537
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.
Roman T; Rohde LA; Hutz MH
Am J Pharmacogenomics; 2004; 4(2):83-92. PubMed ID: 15059031
[TBL] [Abstract][Full Text] [Related]
30. Association study and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder.
Grünblatt E; Werling AM; Roth A; Romanos M; Walitza S
J Neural Transm (Vienna); 2019 Apr; 126(4):517-529. PubMed ID: 30923918
[TBL] [Abstract][Full Text] [Related]
31. The VNTR polymorphism in the human dopamine transporter gene: improved detection and absence of association of VNTR alleles with attention-deficit hyperactivity disorder.
Simsek M; Al-Sharbati M; Al-Adawi S; Lawatia K
Genet Test; 2006; 10(1):31-4. PubMed ID: 16545000
[TBL] [Abstract][Full Text] [Related]
32. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.
Kereszturi E; Tarnok Z; Bognar E; Lakatos K; Farkas L; Gadoros J; Sasvari-Szekely M; Nemoda Z
Am J Med Genet B Neuropsychiatr Genet; 2008 Dec; 147B(8):1431-5. PubMed ID: 18214865
[TBL] [Abstract][Full Text] [Related]
33. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder.
Cheon KA; Cho DY; Koo MS; Song DH; Namkoong K
Biol Psychiatry; 2009 Apr; 65(7):564-70. PubMed ID: 19150055
[TBL] [Abstract][Full Text] [Related]
34. Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.
Bonvicini C; Faraone SV; Scassellati C
Mol Psychiatry; 2016 Jul; 21(7):872-84. PubMed ID: 27217152
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
36. Functional genomics of attention-deficit/hyperactivity disorder (ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects.
Spencer TJ; Biederman J; Faraone SV; Madras BK; Bonab AA; Dougherty DD; Batchelder H; Clarke A; Fischman AJ
Biol Psychiatry; 2013 Jul; 74(2):84-9. PubMed ID: 23273726
[TBL] [Abstract][Full Text] [Related]
37. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.
Kim BN; Cummins TD; Kim JW; Bellgrove MA; Hong SB; Song SH; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
Int J Neuropsychopharmacol; 2011 Nov; 14(10):1399-410. PubMed ID: 21733227
[TBL] [Abstract][Full Text] [Related]
38. Relationship between the DAT1 gene and the effects of methylphenidate administration in adult attention deficit hyperactivity disorder: a magnetic resonance spectroscopy study.
Inci Kenar AN; Ünal GA; Güler H; Albuz B; Kıroğlu Y; Erdal ME; Herken H
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1373-8. PubMed ID: 27097961
[TBL] [Abstract][Full Text] [Related]
39. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
40. Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample.
Laucht M; Skowronek MH; Becker K; Schmidt MH; Esser G; Schulze TG; Rietschel M
Arch Gen Psychiatry; 2007 May; 64(5):585-90. PubMed ID: 17485610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
